SCHEMBL2375183

SCHEMBL2375183

Cc1ccc(C=CC(=O)N(Cc2ccc(N3CCOCC3)nc2)[C@@H](Cc2ccccc2)C(=O)N2CCOCC2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
NPC1 O15118 1/20 0.42
KDM4E B2RXH2 3/20 0.40
MAPT P10636 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C19 P33261 1/20 0.40
SNCA P37840 1/20 0.40
CYP11B1 P15538 1/20 0.39
CYP11B2 P19099 1/20 0.39
THRB P10828 1/20 0.39
HCRTR2 O43614 1/20 0.39
MMP8 P22894 1/20 0.38
GPR183 P32249 1/20 0.38
RORC P51449 1/20 0.38
AOC3 Q16853 2/20 0.38
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.36
TRPM8 Q7Z2W7 1/20 0.36
MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2375186 1.00 RAB9A (0.42) RAB9ASMN1; SMN2NPC1KDM4EMAPT
SCHEMBL2375180 1.00 RAB9A (0.42) RAB9ASMN1; SMN2NPC1KDM4EMAPT
SCHEMBL2375134 0.93 KDM4E (0.42) RAB9ASMN1; SMN2NPC1KDM4EMAPT
SCHEMBL2375149 0.93 KDM4E (0.42) RAB9ASMN1; SMN2NPC1KDM4EMAPT
SCHEMBL2375139 0.93 KDM4E (0.42) RAB9ASMN1; SMN2NPC1KDM4EMAPT
SCHEMBL2373752 0.93 LMNA (0.49) KDM4EMAPTALDH1A1LMNAMEN1
SCHEMBL2373756 0.93 LMNA (0.49) KDM4EMAPTALDH1A1LMNAMEN1
SCHEMBL2373754 0.93 LMNA (0.49) KDM4EMAPTALDH1A1LMNAMEN1
SCHEMBL2374610 0.92 TRPM8 (0.42) RAB9ASMN1; SMN2NPC1KDM4EMAPT
SCHEMBL2374607 0.92 TRPM8 (0.42) RAB9ASMN1; SMN2NPC1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110224210-A1 NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS ACTELION PHARMACEUTICALS LTD. (CH) 2011-09-15 US claimed
US-20110224210-A1 NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS ACTELION PHARMACEUTICALS LTD. (CH) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224210-A1 NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS CTSA, BECN1, HDAC6 RAB9A 538/4885SMN1; SMN2 4567/4885NPC1 1403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.